Allergic Rhinitis Treatment Market Size Estimated to Reach $16.3 Billion by 2027

“Allergic Rhinitis Treatment Market | IndustryARC”

Allergic Rhinitis Treatment Market size is estimated to reach $16.3 billion by 2027, growing at a CAGR of 3.4% during the forecast period 2022-2027. Allergic Rhinitis Treatment as its most excellent course of treatment involves recognizing and staying away from allergens that bring about the symptoms. If it is not completely avertable, steps need to be taken to reduce the exposure. Antihistamines, Decongestants, Corticosteroids, and Immunotherapy are some treatment options for healing Allergic Rhinitis. Pharmacologic alternatives for the treatment of allergic rhinitis involve intranasal corticosteroids, oral and intranasal antihistamines, decongestants, intranasal cromolyn, intranasal anticholinergics, and leukotriene receptor, antagonists. If there is a specifically serious bout of symptoms and accelerated alleviation is required, a brief course of corticosteroid tablets lasting 5 to 10 days may be prescribed.

The raised risk of allergic rhinitis owing to people residing in unhygienic environments requiring the application of antihistamines is set to drive the Allergic Rhinitis Treatment Market. The proliferating inclination of the Medical Guild to eliminate hay fever viruses is set to propel the growth of the Allergic Rhinitis Treatment Market during the forecast period 2022-2027. This represents the Allergic Rhinitis Treatment Industry Outlook.

Allergic Rhinitis Treatment Market Segment Analysis – By Type:

The Allergic Rhinitis Treatment Market based on type can be further segmented into Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Occupational Allergic Rhinitis. The Perennial Allergic Rhinitis Segment held the largest market share in 2021. This growth is owing to the surging pervasiveness of perennial allergic rhinitis worldwide. Antihistamines like Cetirizine hydrochloride, Diphenhydramine, Fexofenadine, and Loratadine are recommended for curbing allergy symptoms. The enormous pool of patients is further propelling the growth of the Perennial Allergic Rhinitis segment.
Furthermore, the Seasonal Allergic Rhinitis segment is estimated to grow with the fastest CAGR of 3.7% during the forecast period 2022-2027 owing to the increasing predominance of seasonal allergic rhinitis wherein the immune system of the person misjudges an allergen like pollen as an intruder much like bacteria or virus and antihistamines like Desloratadine are designated for the alleviation of nasal and non-nasal symptoms of seasonal allergic rhinitis.

For More Information About Allergic Rhinitis Treatment Market @

https://www.industryarc.com/Report/15389/allergic-rhinitis-market.html

Report Price: $ 4500 (Single User License)

Allergic Rhinitis Treatment Market Segment Analysis – By Treatment:

The Allergic Rhinitis Treatment Market based on treatment can be further segmented into Antihistamines, Corticosteroids, Immunotherapy, Decongestants, and Others. The Antihistamines Segment held the largest market share in 2021. This growth is owing to the soaring application of Oral H1 antihistamines as first-line therapy for mild-to-moderate allergic rhinitis. Certain novel oral antihistamines, like cetirizine, desloratadine, and fexofenadine, have been demonstrated to alleviate the symptom of nasal congestion. The surging application of antihistamines for the treatment of perennial allergic rhinitis and seasonal allergic rhinitis is further propelling the growth of this segment.
Furthermore, the Corticosteroids segment is estimated to grow with the fastest CAGR of 3.9% during the forecast period 2022-2027 owing to the surging application of nasal corticosteroids utilized to alleviate inflammation ad itching being accessible as sprays.

Allergic Rhinitis Treatment Market Segment Analysis – By Geography:

The Allergic Rhinitis Treatment Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Allergic Rhinitis Treatment Market) held the largest share with 35% of the overall market in 2021. The growth of this region is owing to the increasing predominance of allergic rhinitis requiring the application of antihistamines in the region. The surging awareness of allergic rhinitis and the proliferating financing for research for early treatment alternatives are further driving the growth of the Allergic Rhinitis Treatment Market in this region. The access to progressive treatment solutions is further propelling the growth of the Allergic Rhinitis Treatment Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the rising pervasiveness of allergic rhinitis requiring the application of antihistamines in the Asia-Pacific region. The enormous patient pool, surging demand for excellent treatment options, and heightening spending on healthcare are further fuelling the progress of the Allergic Rhinitis Treatment Market in the Asia-Pacific region.

Allergic Rhinitis Treatment Market Drivers

Surging Applications Of Immunotherapy For Allergic Rhinitis Are Projected To Drive The Growth Of Allergic Rhinitis Treatment Market:

Allergic rhinitis is one of the most typical allergic ailments and is characterized by sneezing, rhinorrhea, nasal congestion, and nasopharyngeal itching. Subcutaneous immunotherapy (SCIT) for particular allergens is an efficient treatment and activates the inhibitory impact of T regulatory lymphocytes and reduces clinical symptoms in allergic rhinitis. Subcutaneous Immunotherapy activates tolerance in T lymphocytes, specifically by boosting T regulatory cells cytokines, TGF beta, and IL10. Allergen immunotherapy is the repetitive application of allergen concentrates to allergic individuals to offer long-term alleviation of symptoms and enhancement in quality of life at the time of consequent organic allergen exposure. Allergen immunotherapy is greatly efficient in IgE (Immunoglobulin E)-mediated ailment in patients with a restricted spectrum (1 or 2) of allergies. Organized examinations have demonstrated that subcutaneous injection immunotherapy is greatly efficient in allergic rhinitis, in patients with seasonal pollinosis, and also in patients with perennial allergy and sensitivity to house dust mites. The surging applications of immunotherapy for allergic rhinitis are therefore fuelling the growth of the Allergic Rhinitis Treatment Market during the forecast period 2022-2027.

Proliferating Applications Of Intranasal Corticosteroids Are Expected To Boost The Demand Of Allergic Rhinitis Treatment Market:

Intranasal corticosteroids are acknowledged as secure and efficient earliest-line therapy for allergic rhinitis. Numerous intranasal corticosteroids are accessible: beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate, and triamcinolone acetonide. All are effective in treating seasonal allergic rhinitis and as prophylaxis for perennial allergic rhinitis. Typically, they alleviate nasal congestion and itching, rhinorrhea, and sneezing that happen in the early and late stages of allergic response, with investigations demonstrating almost total avoidance of late-phase symptoms. The rationale for topical intranasal corticosteroids in the treatment of allergic rhinitis is that sufficient medication concentrations can be accomplished at receptor sites in the nasal mucosa. This results in symptom control and minimizes the hazard of integral adverse impacts. The proliferating applications of intranasal corticosteroids are driving the growth of the Allergic Rhinitis Treatment Market during the forecast period 2022-2027.

Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=15389

Allergic Rhinitis Treatment Market Challenges

Challenges In Management Of Allergic Rhinitis Are Hampering The Growth Of The Allergic Rhinitis Treatment Market:

There are many impediments in the path of efficient allergy management typically and curbing of allergic rhinitis (AR) particularly. An over-dependence on randomized controlled trials to direct AR guideline suggestions, the requirement for a wider interpretation of the AR evidence base to involve randomized controlled trials and real-life investigations, poorly planned and interpreted investigations and dearth of an AR control concept and typical language of control are some challenges in allergic rhinitis management. Investigations have demonstrated that not treating allergic rhinitis can result in raised asthma costs and hospitalization. These issues are thus hampering the growth of the Allergic Rhinitis Treatment Market.

Allergic Rhinitis Treatment Market Landscape:

Product launches, mergers and acquisitions, joint ventures, and R&D Activities are key strategies adopted by players in the Allergic Rhinitis Treatment Market. Key companies of this market are:

Sanofi
Cigna
Himalaya
Johnson & Johnson
Merck
GSK
Glenmark Pharmaceuticals
Boehringer Ingelheim International GmbH
Covis Pharma
FAES Farma SA

Recent Developments

In October 2021, Cigna extended its virtual care and telehealth platform by offering a greater array of virtual healthcare services for its members, raising provider access to patient health information, and introducing a virtual-first health plan. The extension comes six months consequent to Cigna’s health services business Evernorth gaining the telehealth platform MDLIVE.

Cigna members will have access to virtual-first primary, dermatology, behavioral, and urgent care services, the payer pronounced.

In September 2021, Glenmark became the earliest firm to introduce Remogliflozin + Vildagliptin + Metformin fixed-dose integration (FDC) medication at an affordable price for mature grown-ups with Type 2 Diabetes. India is the earliest nation to acquire access to this FDC medication. Glenmark accepted endorsement for the medication from the Drug Controller General of India (DCGI) for manufacturing and marketing in late September 2021.

In August 2021, Cigna International declared the introduction of the Cigna StressWaves Test, a free online tool that investigates acoustic and semantic voice patterns to assess stress levels. The StressWaves Test was developed in partnership with Ellipsis Health, a medical technology developer and leader in AI health and vocal biomarkers. The StressWaves Test will disclose the user’s stress level, ranging from ‘Extremely Stressed’ to ‘No Stress’, together with a portrait that envisions the impact of stress on the body and mind of the user.

Key Takeaways

Geographically, the North American Allergic Rhinitis Treatment Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging progress in disease treatment involving antihistamines in the North American region.

Allergic Rhinitis Treatment Market growth is being driven by the increasing predominance of Allergic Rhinitis brought about by allergens like grass, pollen, dust, dander, molds, or animal saliva requiring application of antihistamines. However, the inadequate alleviation in symptoms in certain patients offered by certain presently regarded first-line Allergic Rhinitis treatments in real life is one of the major factors hampering the growth of the Allergic Rhinitis Treatment Market.

Allergic Rhinitis Treatment Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Allergic Rhinitis Treatment Market report.

Related Reports-

Perennial Allergic Rhinitis Market

https://www.industryarc.com/Report/15981/perennial-allergic-rhinitis-market.html

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/